Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of rinatabart sesutecan versus investigator's choice chemotherapy in recurrent or advanced endometrial cancer after platinum and PD(L)1 therapy
MOH_2026-03-29_015739Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in endometrial cancer (EC) (2 arms), sponsored by Genmab. Started Mar 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2026-03-29_015739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-29_015739.